ReviewAmerican journal of cancer research2026
Advances in ferroptosis research in ovarian cancer: molecular mechanisms and therapeutic perspectives.
Review in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is one of the most aggressive malignancies in the female genital system and presents a poor prognosis. Its high rate of recurrence and emergence of acquired resistance to the current chemotherapeutic approaches significantly restrict its long-term therapeutic efficacy. While treatment strategies including cytoreductive surgery (CRS) plus platinum (Pt)-based chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have brought clinical benefits to a proportion of patients, the majority eventually suffer cancer relapse post-treatment. This finding suggests that classical forms of cell death may not fully explain treatment outcomes, survival, and resistance in ovarian cancer. Ferroptosis is a nonapoptotic mode of cell death that results from the iron-dependent and lethal peroxidation of lipids. Its onset and progression are contextually regulated by iron homeostasis, lipid metabolism, and redox balance, and also tightly involved in the tumor metabolic reprogramming and adaptation to the tumor microenvironment (TME). Under therapeutic pressure, ovarian cancer cells may become more susceptible to ferroptosis while simultaneously suppressing ferroptotic cell death through multilayered regulatory systems, including glutathione peroxidase 4 (GPX4) and the cystine/glutamate antiporter system (system Xc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.